HC Wainwright Cuts Femasys (NASDAQ:FEMY) Price Target to $12.00

Femasys (NASDAQ:FEMY) had its price target trimmed by HC Wainwright from $13.00 to $12.00 in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Femasys Trading Up 12.9 %

Shares of NASDAQ FEMY opened at $1.05 on Friday. The company has a market cap of $23.33 million, a price-to-earnings ratio of -1.25 and a beta of -2.81. The stock’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $1.30. The company has a current ratio of 8.43, a quick ratio of 8.02 and a debt-to-equity ratio of 0.29. Femasys has a 12-month low of $0.25 and a 12-month high of $4.75.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Femasys had a negative net margin of 1,420.59% and a negative return on equity of 104.06%. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.50 million. Equities research analysts expect that Femasys will post -0.72 EPS for the current year.

Institutional Investors Weigh In On Femasys

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC boosted its stake in Femasys Inc. (NASDAQ:FEMY) by 30.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 309,274 shares of the company’s stock after buying an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned 1.40% of Femasys worth $479,000 at the end of the most recent quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.